10-K: Cellectar Biosciences Faces Going Concern Doubt Amid R&D Focus

Cellectar Biosciences reports significant losses and a going concern warning for 2025, despite positive clinical data for iopofosine I 131 and other PDC programs.

Summary

• Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on cancer treatment using its proprietary Phospholipid Ether Drug Conjugate (PDC) platform.
• The company's lead programs are radioconjugates: iopofosine I 131 (beta-emitting), CLR 125 (Auger-emitting), and CLR 225 (alpha-emitting).
• Iopofosine I 131 received FDA Breakthrough Therapy Designation on June 4, 2025, for relapsed/refractory Waldenstrom macroglobulinemia (r/r WM).
• The European Medicines Agency (EMA) advised on October 6, 2025, that a Conditional Marketing Authorization (CMA) filing for iopofosine I 131 in post-BTKi refractory WM patients could be acceptable.
• The CLOVER WaM Phase 2 study for r/r WM met its primary endpoint with a major response rate (MRR) of 58.2% (95% CI [44.50%, 75.80%], p < 0.0001), exceeding the FDA's 20% statistical hurdle.
• The CLOVER WaM study also showed an overall response rate (ORR) of 83.6%, disease control in 98.2% of patients, and a 7.3% complete remission (CR) rate in this highly refractory WM population.
• Iopofosine I 131 was well tolerated in CLOVER WaM, with no treatment-related deaths, though common Grade 3 or greater treatment-related adverse events (TRAEs) included thrombocytopenia (81.5%), neutropenia (66.2%), and anemia (47.7%).
• An End-of-Phase-2 (EOP2) meeting with the FDA on March 6, 2025, outlined a path for potential accelerated and full approval of iopofosine I 131 for WM, contingent on initiating a confirmatory Phase 3 trial, which is dependent on funding.
• CLR 125 is prepared to enter a Phase 1b clinical trial in 2025 for triple-negative breast cancer (TNBC), having shown good preclinical activity and tolerability.
• CLR 225 is prepared to initiate a Phase 1 imaging and dose escalation safety study, subject to obtaining additional financing, after demonstrating activity in multiple solid tumor animal models.
• The company reported a net loss of approximately $21.8 million for the year ended December 31, 2025, a decrease from $44.6 million in 2024.
• Research and development expenses decreased by 56% to $11.5 million in 2025 from $26.1 million in 2024, primarily due to the conclusion of WM clinical study enrollment.
• General and administrative expenses decreased by 55% to $11.5 million in 2025 from $25.6 million in 2024, driven by reduced pre-commercialization efforts and personnel costs.
• Cash and cash equivalents were $13.2 million as of December 31, 2025, down from $23.3 million in 2024, with approximately $23.1 million used in operating activities during 2025.
• Management believes current cash is adequate to fund operations into the third quarter of 2026, but the auditor's report raises substantial doubt about the company's ability to continue as a going concern without additional funding.
• The company completed an underwritten public offering in July 2025, raising approximately $6.9 million gross proceeds, and a warrant exercise inducement in October 2025, generating approximately $5.8 million gross proceeds.
• A 1-for-30 reverse stock split was effected on June 24, 2025, to regain compliance with Nasdaq's minimum bid price requirement.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a high-risk situation. While the clinical data for iopofosine I 131 is promising and regulatory designations are positive, the company's severe liquidity issues and explicit going concern warning indicate significant financial instability and a high dependency on future capital raises, which may or may not materialize on favorable terms.

Positives

• Iopofosine I 131 received FDA Breakthrough Therapy Designation for relapsed/refractory Waldenstrom macroglobulinemia (r/r WM) on June 4, 2025.
• The EMA's Scientific Advice Working Party (SAWP) advised on October 6, 2025, that a Conditional Marketing Authorization (CMA) filing for iopofosine I 131 in post-BTKi refractory WM patients could be acceptable.
• The CLOVER WaM Phase 2 study for r/r WM met its primary endpoint with a major response rate (MRR) of 58.2%, significantly exceeding the FDA's agreed-upon statistical hurdle of 20%.
• The CLOVER WaM study demonstrated a high overall response rate (ORR) of 83.6% and disease control in 98.2% of evaluable patients.
• Responses in the CLOVER WaM study were durable, with median duration of response not reached at 11.4 months of follow-up and 76% of patients remaining progression-free at a median follow-up of eight months.
• Iopofosine I 131 monotherapy achieved a 7.3% complete remission (CR) rate in a highly refractory WM population.
• Iopofosine I 131 was well tolerated in the CLOVER WaM study, with no treatment-related deaths reported.
• The FDA End-of-Phase-2 (EOP2) meeting on March 6, 2025, provided a clear path for potential accelerated and full approval of iopofosine I 131 for WM.
• CLR 125 (Auger-emitting PRC) showed tolerability with minimal toxicities and good activity in multiple solid tumor models, especially triple-negative breast cancer, in preclinical evaluations.
• CLR 225 (alpha-emitting PRC) demonstrated activity in multiple solid tumor animal models, including pancreatic, colorectal, and breast cancers, and was well tolerated with no adverse events at the highest doses tested.
• Iopofosine in combination with external beam radiation (EBRT) achieved a 64% complete remission rate and 73% ORR (n=11) in a Phase 1 investigator-initiated study for recurrent head and neck cancer, with observed durability of tumor control.
• The company has established a collaborative outsourcing model for manufacturing, utilizing a decentralized network of contract manufacturers like AtomVie and SpectronRx.
• A multi-year supply agreement with Ionetix Corporation for Actinium-225 (Ac-225) and Astatine-211 (At-211) was announced in December 2025.
• The company was granted Small and Medium-Sized Enterprise (SME) status by the EMA in June 2020, providing significant financial incentives and fee reductions for scientific advice and regulatory filings.
• Iopofosine has received multiple Orphan Drug Designations (ODDs) and Rare Pediatric Disease Designations (RPDDs) in the U.S. and PRIME designation and ODD in Europe for various cancer indications.
• Successful capital raises in July 2025 (approximately $6.9 million gross) and October 2025 (approximately $5.8 million gross) provided additional funding.

Negatives

• The company has incurred significant recurring losses and negative cash flows from operations since its inception, with an accumulated deficit of approximately $269 million as of December 31, 2025.
• Reported a net loss of approximately $21.8 million for the year ended December 31, 2025.
• Used approximately $23.1 million in cash for operating activities during the year ended December 31, 2025.
• Cash and cash equivalents of $13.2 million as of December 31, 2025, are only adequate to fund operations into the third quarter of 2026, raising substantial doubt about the company's ability to continue as a going concern.
• Fatalities have occurred in patients post-treatment with iopofosine in the CLOVER-1 Phase 2b study for r/r multiple myeloma (MM) and central nervous system lymphoma (CNSL).
• Common Grade 3 or greater treatment-related adverse events (TRAEs) observed in the CLOVER WaM study included thrombocytopenia (81.5%), neutropenia (66.2%), anemia (47.7%), and decreased white blood cell count (27.7%).
• The initiation of the confirmatory Phase 3 trial for iopofosine I 131 in WM is dependent on obtaining sufficient additional funding.
• The initiation of a Phase 1 imaging and dose escalation safety study for CLR 225 is subject to the company's ability to obtain additional financing.
• Identified material weaknesses in internal control over financial reporting as of December 31, 2024, which led to the restatement of previously issued financial statements and could result in future material misstatements.
• The company is heavily dependent on outside capital to fund its operations for the foreseeable future.
• The EU's newly adopted pharmaceutical legislation, expected to apply in 24 months, includes a one-year reduction in baseline regulatory market protection and strict conditions for recouping lost protection, which could negatively impact future product commercialization.
• The company's common stock price has been and continues to be highly volatile.
• Received a Nasdaq deficiency letter on January 30, 2025, for failing to meet the $1.00 minimum bid price requirement, although compliance was regained after a 1-for-30 reverse stock split on June 24, 2025.

Risks

• Will require additional capital to continue operations and may have difficulty raising it, raising substantial doubt about the company's ability to continue as a going concern.
• Ability to utilize net operating loss carryforwards and certain other tax attributes may be limited under Sections 382 and 383 of the Internal Revenue Code.
• Reliance on a collaborative outsourced business model; disruptions with third-party collaborators may impede FDA approval and delay or impair commercialization of any products.
• Cannot assure the successful development and commercialization of compounds in development.
• Failure to complete the development of technologies, obtain government approvals (including FDA), or comply with ongoing governmental regulations could prevent, delay, or limit product introduction or sale.
• Fast track designation by the FDA may not actually lead to a faster development or regulatory review or approval process and does not assure FDA approval.
• May not be able to realize any value from the Rare Pediatric Disease Designation (RPDD) for iopofosine.
• Failure to meet the EU's Conditional Marketing Authorization (CMA) conditions, particularly the unmet needs condition, means requiring marketing authorization through the normal approval process, which requires more robust data.
• Clinical studies involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies may not be predictive of future study results.
• May be required to suspend or discontinue clinical studies because of unexpected side effects or other safety risks that could preclude approval of product candidates.
• Controls to ensure compliance with all applicable laws and regulations may not be effective.
• Exposed to product, clinical, and preclinical liability risks that could create a substantial financial burden.
• Regulatory drug designations such as orphan drug classification may not confer marketing exclusivity or other expected commercial benefits.
• May face litigation from third parties claiming products infringe on their intellectual property rights.
• If unable to adequately protect or enforce intellectual property rights or secure rights to third-party patents, may lose valuable rights, experience reduced market share, or incur costly litigation.
• Reliance on a small number of key personnel; success depends on ability to hire additional qualified personnel.
• Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and other proprietary information.
• May be subject to claims that employees have wrongfully used or disclosed alleged trade secrets of their current or former employers.
• Acceptance of products in the marketplace is uncertain; failure to achieve market acceptance will prevent or delay ability to generate revenues.
• Any approved product is subject to extensive ongoing regulatory requirements; failure to comply or unanticipated problems could lead to penalties, inability to generate revenue, and increased capital needs.
• If third-party contractors fail to perform their responsibilities to comply with FDA rules and regulations, marketing and sales of products could be delayed and subject to enforcement action.
• Unforeseen safety issues could emerge with products, once approved, requiring changes to prescribing information, limiting use, or resulting in litigation.
• The market for proposed products is rapidly changing and competitive; new therapeutics, drugs, and treatments developed by others could impair business.
• May be unsuccessful in efforts to sell proposed products, develop a direct sales organization, or enter into relationships with third parties.
• If unable to convince physicians of the benefits of intended products, may incur delays or additional expense in establishing market acceptance.
• If products are unable to obtain adequate reimbursement from third-party payors, or if additional healthcare reform measures are adopted, it could hinder or prevent commercial success.
• Enacted and future legislation may increase the difficulty and cost for commercializing product candidates and may affect prices.
• May be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and other federal and state healthcare laws; failure to comply could result in substantial penalties.
• Employees, independent contractors, consultants, principal investigators, CROs, commercial partners, and vendors may engage in misconduct or other improper activities.
• Identified material weaknesses in internal control over financial reporting, which resulted in financial statement restatement and could adversely affect ability to meet reporting requirements.
• Failure to meet Nasdaq's continued listing requirements could result in delisting of common stock.
• Common stock price could be further diluted as a result of the issuance of additional shares of common stock, convertible securities, warrants, or options.
• Provisions of certificate of incorporation, by-laws, and Delaware law may make an acquisition or change in management more difficult.
• Conflicts, military actions, terrorist attacks, natural disasters, public health crises, cyber-attacks, and general instability could adversely affect business.
• Business and operations may be materially adversely affected in the event of computer system failures or security breaches.
• Failure to meet investor and stakeholder expectations regarding environmental, social, and corporate governance (ESG) matters may damage reputation.

Future Outlook

The company expects to continue generating operating losses for the foreseeable future and is actively pursuing additional funding through equity/debt sales or strategic transactions, alongside implementing cost-saving measures, to address its liquidity challenges. The submission of a New Drug Application (NDA) for accelerated approval of iopofosine I 131 for WM is planned once a confirmatory Phase 3 trial is underway, which itself is dependent on securing sufficient funding. CLR 125 is prepared to enter a Phase 1b clinical trial in 2025, and CLR 225 is prepared to initiate a Phase 1 imaging and dose escalation safety study, also contingent on additional financing. The final clinical study report for the Phase 1 Multiple Myeloma study is anticipated in the first half of 2026. The company is also exploring strategic alternatives to advance its platform and pipeline, and notes that new EU pharmaceutical legislation, expected to apply in 24 months, will reduce baseline regulatory market protection and introduce launch and supply obligations.

Management Comments

• We believe that our PDC platform possesses the potential for the discovery and development of the next generation of cancer-targeting treatments, and we plan to develop PDCs both independently and through research and development collaborations.
• We believe this profile differentiates our PRCs from many traditional on-market treatments and radiotherapeutics.
• We believe that to cause the necessary breakage of the tumor cell DNA, the isotope must get inside the cell and near the cell nucleus to be effective. The Company believes that CLR 125 achieves this condition because of the Companys novel phospholipid ether drug conjugate platform.
• To further develop iopofosine I 131, the Company will likely require either a strategic partner with the necessary resources or sufficient additional funding to initiate and at least partially enroll a confirmatory study, which has been identified as a required predicate to the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the accelerated approval of iopofosine I 131 as a treatment for WM.
• We believe this may represent an important improvement in the treatment of r/r WM as we believe no approved or late-stage development treatments for secondand third-line patients have reported a CR to date.
• Our assessment is that these cytopenias have had a predictable pattern to initiation, nadir and recovery and are treatable.
• We believe that these data support the notion of enhanced patient outcomes when combining the use of iopofosine I 131 in combination with external beam radiation for a treatment of solid tumors.
• We believe our PDC platform has potential to provide targeted delivery of a diverse range of oncologic payloads.
• We believe that the capability of our technology to target and be selectively retained by cancer stem cells in vivo was demonstrated by treating glioma stem cell-derived orthotopic tumor-bearing mice with another fluorescent-labeled PDC (CLR 1501), and then removing the tumor and isolating cancer stem cells, which continued to display CLR 1501 labeling even after three weeks in cell culture.
• We believe our targeted delivery technology has the potential to achieve these goals (selective delivery of effective doses of isotopes that destroy tumor tissue, sparing of surrounding normal tissue, and non-accumulation in vital organs).
• While management believes their plans will be successful, no assurance can be provided such plans will be effectively implemented over the next twelve months beyond the issuance date (regarding securing additional outside capital and preserving liquidity).

Industry Context

StockSavvy.ai notes that Cellectar Biosciences operates within the rapidly growing global cancer drug market, estimated at $215 billion in 2026 and projected to reach $555 billion by 2035. The company's focus on radioconjugate Phospholipid Drug Conjugates (PDCs) aligns with the increasing adoption of radioligand therapies, a key growth driver in oncology. The company targets rare and difficult-to-treat cancers like Waldenstrom macroglobulinemia (WM), multiple myeloma (MM), and high-grade gliomas, which represent significant unmet medical needs and often command premium pricing, potentially offering a niche for its specialized therapies. The market for solid tumors alone is projected to reach $375.4 billion by 2034, indicating substantial opportunity for new targeted treatments like CLR 125 and CLR 225.

Comparison to Industry Standards

• Iopofosine I 131 in the CLOVER WaM study for relapsed/refractory Waldenstrom macroglobulinemia (r/r WM) achieved a 58.2% Major Response Rate (MRR) and a 7.3% Complete Remission (CR) rate. These outcomes significantly exceed historic real-world data, which typically show a 4-12% MRR and a duration of response of approximately six months or less in less pretreated patient populations.
• For highly refractory Multiple Myeloma (MM) patients, iopofosine demonstrated an Overall Response Rate (ORR) of 45.5% and a Clinical Benefit Rate (CBR) of 72.7% in triple-class refractory patients. In a subset of quad/penta drug refractory patients, efficacy increased to an 80% ORR and 100% CBR, which is notable given these patients had a median of over seven prior therapies and represent a very challenging treatment population.
• In a Phase 1 investigator-initiated study for recurrent Head and Neck Cancer (HNC), iopofosine I 131 in combination with external beam radiation treatment (EBRT) achieved a 64% Complete Remission (CR) and 73% ORR (n=11), with 73% overall survival and 36% progression-free survival at 12 months. These results are presented as an 'enhanced patient outcome' compared to standard re-irradiation approaches that often cause severe normal tissue injury.
• The company's Phospholipid Drug Conjugate (PDC) platform is highlighted for its mechanism of entry, which does not rely on specific cell surface epitopes or antigens, differentiating it from other targeted delivery platforms. This approach is believed to offer broader applicability across tumor types and cancer stem cells, potentially overcoming limitations of therapies targeting specific surface epitopes that may not be present on all tumor cells or normal tissue.

Corporate Governance

Legal Proceedings

• The company may be a party to proceedings in the ordinary course of business, but does not anticipate that the outcome of such matters and disputes will materially affect its financial statements.

Stakeholder Impact

• Shareholders face potential significant dilution from future equity capital raises, high stock price volatility, and the risk of delisting from Nasdaq if compliance requirements are not maintained. The going concern warning indicates a high risk of substantial losses.
• Employees experienced a workforce reduction plan in December 2024, impacting approximately 60% of staff. The company's success depends on attracting and retaining highly skilled personnel, with stock-based compensation used as an incentive.
• Customers and patients could benefit from new, effective treatments for rare and refractory cancers (WM, MM, HGG, sarcomas, TNBC) if product candidates are successfully developed and commercialized. However, development delays or discontinuation due to funding issues pose a risk.
• Suppliers and creditors face risks related to the company's financial instability and going concern doubt, potentially impacting payment timeliness. The company relies heavily on third-party manufacturers and contract research organizations.
• Regulatory bodies will continue to scrutinize the company due to identified material weaknesses in internal controls and the need for continuous compliance with extensive regulations governing drug development and marketing.

Next Steps

• Initiate a comparator-controlled Phase 3 confirmatory trial assessing progression-free survival as the primary endpoint in WM patients (dependent on funding).
• Submit a New Drug Application (NDA) to the FDA for accelerated approval of iopofosine I 131 as a treatment for WM, at the time of Phase 3 initiation and ongoing patient enrollment.
• Initiate a Phase 1b dose finding study for CLR 125 in triple-negative breast cancer (TNBC) (projected for the first half of 2026).
• Initiate a Phase 1 imaging and dose escalation safety study for CLR 225 (subject to additional funding).
• Expect the final clinical study report for the Phase 1 study in r/r Multiple Myeloma (MM) in the first half of 2026.
• Continue to explore a full range of strategic alternatives (mergers, acquisitions, partnerships, joint ventures, licensing arrangements, or other strategic transactions) to advance its platform and radiopharmaceutical drug development pipeline.
• Actively pursue financing alternatives, including the sale of equity and/or debt securities or strategic transactions, to obtain additional funding.
• Preserve liquidity by implementing temporary cost-saving measures as needed.
• Remediate identified material weaknesses in internal control over financial reporting, including recruiting qualified accounting and financial reporting personnel and implementing an ERP system.
• Continue to file patent applications and acquire licenses to other patents covering methods of use, composition of matter, formulation, method of synthesis, and other patentable claims related to iopofosine, CLR 121125, CLR 121225, and new PDCs.
• Explore options for the WM opportunity outside of the US market, seeking to establish arrangements with biotechnology or pharmaceutical companies having strong product development and commercialization expertise and distribution infrastructure in Europe and global markets.

Key Dates

Recommendation

The company faces an existential threat with its 'going concern' warning and limited cash runway into Q3 2026. While clinical data for iopofosine I 131 is positive and regulatory designations are favorable, the immediate need for substantial additional funding to advance its lead candidate to a confirmatory Phase 3 trial, coupled with a history of significant losses and identified material weaknesses in internal controls, presents an extremely high-risk investment profile. The potential for significant dilution from future capital raises or even a wind-down of operations makes the stock a strong sell for risk-averse investors.

Keywords

Cancer treatment, Biopharmaceutical, Phospholipid Drug Conjugate, PDC, Radioconjugate, Iopofosine I 131, Waldenstrom Macroglobulinemia, Multiple Myeloma, CLR 125, CLR 225, FDA Breakthrough Therapy, Orphan Drug Designation, Rare Pediatric Disease Designation, EMA Conditional Marketing Authorization, Clinical Trials, Oncology, Radiotherapeutics, Drug Development, Going Concern, Capital Raise, Internal Controls